AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

By Bhanvi Satija and Maggie Fick LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with ...

Pfizer PFE and AstraZeneca AZN are two global pharmaceutical leaders with a commanding presence in oncology. For Pfizer, oncology is a key growth driver, accounting for roughly 27% of total company ...

An infectious disease expert has dismissed calls for more COVID vaccine makers to withdraw their jabs. Here’s why.

Senator Ron Johnson leveled explosive accusations against the FDA during a heated Senate Permanent Subcommittee on ...

Pfizer is focusing on India for future growth. The company plans to launch new medicines quickly and at affordable prices.